Canagliflozin and cardiovascular outcomes in Type 2 diabetes

被引：2
|
作者：
Sarraju, Ashish [1 ,2 ]
Spencer-Bonilla, Gabriela [3 ]
Rodriguez, Fatima [1 ,2 ]
Mahaffey, Kenneth W. [1 ,2 ,4 ]
机构：
[1] Stanford Univ, Sch Med, Div Cardiovasc Med, Stanford, CA 94305 USA
[2] Stanford Univ, Sch Med, Cardiovasc Inst, Stanford, CA 94305 USA
[3] Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA
[4] Stanford Ctr Clin Res, Stanford, CA 94304 USA
来源：
FUTURE CARDIOLOGY | 2020年 / 17卷 / 01期
基金：
美国国家卫生研究院;
关键词：
canagliflozin; cardiovascular disease; chronic kidney disease; nephropathy; SGLT2; sodium glucose; cotransporter; 2; inhibitors; Type; diabetes; HEART-DISEASE; CVD-REAL; EFFICACY; SAFETY; INHIBITORS; METFORMIN; RISK; GLIMEPIRIDE; FAILURE; PROFILE;
D O I：
10.2217/fca-2020-0029
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SGLT2 inhibitors have risen to prominence in recent years as Type 2 diabetes mellitus medications with favorable effects on cardiovascular (CV) and renal outcomes. Canagliflozin is a US FDA-approved SGLT2 inhibitor that has demonstrated CV and renal outcome benefits in large scale placebo-controlled randomized trials of patients with Type 2 diabetes mellitus and elevated CV risk. Canagliflozin use may also be associated with serious and nonserious adverse effects requiring ongoing monitoring in patients initiated on this medication. This paper provides a detailed overview of canagliflozin including its pharmacologic profile, clinical efficacy and safety data, with discussion of both clinical trial results, as well as real-world evidence.
引用
收藏
页码：39 / 48
页数：10
相关论文
共 50 条
  • [1] Canagliflozin and cardiovascular and renal events in type 2 diabetes
    Guthrie, Robert
    [J]. POSTGRADUATE MEDICINE, 2018, 130 (02) : 149 - 153
  • [2] Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
    Rajagopalan, Sanjay
    Brook, Robert
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (21): : 2098 - 2099
  • [3] Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
    Neal, Bruce
    Perkovic, Vlado
    Mahaffey, Kenneth W.
    de Zeeuw, Dick
    Fulcher, Greg
    Erondu, Ngozi
    Shaw, Wayne
    Law, Gordon
    Desai, Mehul
    Matthews, David R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (07): : 644 - 657
  • [4] Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
    Perkovic, V.
    Jardine, M. J.
    Neal, B.
    Bompoint, S.
    Heerspink, H. J. L.
    Charytan, D. M.
    Edwards, R.
    Agarwal, R.
    Bakris, G.
    Bull, S.
    Cannon, C. P.
    Capuano, G.
    Chu, P. -L.
    De Zeeuw, D.
    Greene, T.
    Levin, A.
    Pollock, C.
    Wheeler, D. C.
    Yavin, Y.
    Zhang, H.
    Zinman, B.
    Meininger, G.
    Brenner, B. M.
    Mahaffey, K. W.
    McGuire, Darren K.
    Holman, Rury
    Home, Philip
    Scharfstein, Dan
    Parfrey, Patrick
    Shahinfar, Shahnaz
    August, Phyllis
    Chang, Tara
    Sinha, Arjun D.
    Januzzi, James
    Kolansky, Daniel
    Amerena, John
    Hillis, Graham
    Gorelick, Philip
    Kissela, Brett
    Kasner, Scott
    Lindley, Richard
    Fulcher, Greg
    Ounadjela, Souhila
    Hufert, Karina
    von Ingersleben, Gabriele
    Gaglia, Jason
    Harris, Ronald
    Hudson, Margo
    Turchin, Alexander
    Cheifetz, Adam
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (24): : 2295 - 2306
  • [5] Type-2-Diabetes: Canagliflozin reduces cardiovascular Risk
    Lichert, Frank
    [J]. DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2017, 142 (22) : 1647 - 1647
  • [6] Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes Reply
    Neal, Bruce
    Perkovic, Vlado
    Matthews, David R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (21): : 2099 - 2099
  • [7] Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes
    Januzzi, James L.
    Butler, Javed
    Jarolim, Petr
    Sattar, Naveed
    Vijapurkar, Ujjwala
    Desai, Mehul
    Davies, Michael J.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 70 (06) : 704 - 712
  • [8] Effects of canagliflozin on biomarkers of cardiovascular stress in older patients with type 2 diabetes
    Sattar, N.
    Januzzi, J. L.
    Butler, J.
    Jarolim, P.
    Vijapurkar, U.
    Merton, K. W.
    Ren, J.
    Canovatchel, W.
    Desai, M.
    Davies, M. J.
    [J]. DIABETOLOGIA, 2017, 60 : S424 - S424
  • [9] Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus
    Budoff, Matthew J.
    Wilding, John P. H.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2017, 71 (05)
  • [10] Clinical potential of canagliflozin in cardiovascular risk reduction in patients with type 2 diabetes
    Skelley, Jessica W.
    Carter, Brooke S.
    Roberts, Megan Z.
    [J]. VASCULAR HEALTH AND RISK MANAGEMENT, 2018, 14 : 419 - 428
12345